Log in
Enquire now
‌

US Patent 9505827 Animal models and therapeutic molecules

Patent 9505827 was granted and assigned to Kymab on November, 2016 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Kymab
Kymab
Current Assignee
Kymab
Kymab
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9505827
Date of Patent
November 29, 2016
Patent Application Number
13740727
Date Filed
January 14, 2013
Patent Citations Received
‌
US Patent 12004495 Genetically modified non-human animals with humanized immunoglobulin locus
0
‌
US Patent 11707056 Animals, repertoires and methods
0
‌
US Patent 11997994 Genetically modified non-human animals with common light chain immunoglobulin locus
0
Patent Primary Examiner
‌
Anoop Singh
Patent abstract

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9505827 Animal models and therapeutic molecules

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.